

OFFICIALLY LICENSED  
**BEST OF ASCO**<sup>®</sup>  
2020 ANNUAL MEETING

## PROGRAM 2020

Kongresové centrum hotelu Pyramida, čtvrtek 10.září 2020

8:30 – Slavnostní zahájení

### 1.blok karcinom prsu 8:40 – 9.45

1. Primary Analysis of KAITLIN: A Phase 3 Study of Trastuzumab Emtansine (T-DM1) + Pertuzumab Versus Trastuzumab + Pertuzumab + Taxane, after Anthracyclines as Adjuvant Therapy for High-Risk HER2-Positive Early Breast Cancer abst. 500
2. ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106 (504) Tesařová P (12 minut)
3. MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients (506)
4. KEYNOTE-355: Randomized, Double-Blind, Phase 3 Study of Pembrolizumab + Chemotherapy versus Placebo

OFFICIALLY LICENSED  
**BEST OF ASCO**<sup>®</sup>  
2020 ANNUAL MEETING

+ Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (1000) Čmejlova V ( 12 minut)

5. A Randomized, Multicenter, Open-label, Phase II Trial to Evaluate Palbociclib in Combination with Fulvestrant or Letrozole in Endocrine-sensitive Patients with Estrogen Receptor (ER)[+]/HER2[-] Metastatic Breast Cancer: PARSIFAL trial1007)

6. A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer: ECOG-ACRIN 2108(LBA2) Bielčíková Z (12 minut)

Diskuse: Petráková (15 minut)

2. blok karcinom plic 9.45 – 11:00

**NSCLC**

1. ADAURA

Phase III ADAURA: Adjuvant Osimertinib vs Placebo After Complete Resection in Patients With Stage IB-IIIa *EGFR*-Mutated NSCLC

2. CheckMate 9LA trial

CheckMate 9LA: Nivolumab and Ipilimumab Plus 2 Cycles of Platinum-Doublet Chemotherapy vs 4 Cycles Chemotherapy as First-line Treatment for Advanced Non-Small Cell Lung Cancer

3. CitySCAPE trial

Phase II CITYSCAPE: Addition of Tiragolumab, an Anti-TIGIT Antibody, to First-line Atezolizumab in PD-L1–Selected Metastatic NSCLC

4. DESTINY-Lung01

Phase II DESTINY-Lung01: Interim Analysis of Trastuzumab Deruxtecan in Patients With *HER2*-Mutated NSCLC

**SCLC**

5. KEYNOTE-604

KEYNOTE-604 Final Analysis: Addition of Pembrolizumab to Etoposide and Platinum in Extensive-Stage SCLC

## 6. CASPIAN

CASPIAN: Phase III Study of First-line Durvalumab + Tremelimumab + EP vs Durvalumab + EP vs EP Alone in Extensive-Stage SCLC

*Coffee break*

## 3. blok urogenitální karcinomy. 11:15 – 12:30

### Urologie

1. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma: JAVELIN Bladder 100 phase III results
2. Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT and its Impact on Clinical Management of Patients with Biochemically Recurrent Prostate Cancer: Results from a Phase 3, Prospective, Multicenter Study (CONDOR)
3. Overall Survival (OS) Results of Phase III ARAMIS Study of Darolutamide (DARO) Added to Androgen Deprivation Therapy (ADT) for Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC)
4. Updated Overall Survival Results From PROSPER: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide in Men With Nonmetastatic Castration-Resistant Prostate Cancer
5. Final results from SPARTAN

OFFICIALLY LICENSED  
**BEST OF ASCO**<sup>®</sup>  
2020 ANNUAL MEETING

Gynekologie

6. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: the final analysis of AGO DESKTOP III / ENGOT ov20
  
7. Final overall survival results from SOLO2/ENGOT-ov21: a Phase III trial assessing maintenance olaparib in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutationB
  
8. A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer (NRG Oncology GY004)

oběd 12:30 – 13:30

13.30 -14.30 sympozium BMS

OFFICIALLY LICENSED  
**BEST OF ASCO**<sup>®</sup>  
2020 ANNUAL MEETING

4. blok nádory GIT 14:30 – 15:30

1. BEACON CRC: Expanded updated analysis on encorafenib plus cetuximab with or without binimetinib for BRAF V600E–Mutant mCRC. (Independent)
2. Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study (Abstract LBA4)
3. POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC).
4. Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab in combination with durvalumab for patients with advanced hepatocellular carcinoma (Study 22)  
Abstract #4508
5. Abstr. 4004. OS and Long-term DFS of 3 versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-based Therapy for Patients with Stage III Colon Cancer: Final Results from the IDEA Collaboration
6. Trastuzumab With Trimodality Treatment For Esophageal Adenocarcinoma with HER2 Overexpression: A Multicenter Randomized Phase III Trial, NRG Oncology/RTOG 1010  
- negat. studie

OFFICIALLY LICENSED  
**BEST OF ASCO**<sup>®</sup>  
2020 ANNUAL MEETING

7. Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma  
RAMSES/FLOT7 – Results of the phase II-portion of the multicenter, randomized Phase II/III trial of the German AIO and Italian GOIM

- fáze 2, zvýšení R0 rate

8. SWOG S1505: Results of Perioperative Chemotherapy with mFOLFIRINOX vs Gemcitabine/nab-Paclitaxel for Resectable Pancreatic Ductal Adenocarcinoma

15:30 Coffee break a ukončení